Membrane androgen binding sites are preferentially expressed in human prostate carcinoma cells

doi:10.1186/1472-6890-3-1

BMC Clinical Pathology
Volume 3

Viewing options:

Abstract
Full text
PDF (588KB)

Associated material:

Related literature:

Articles citing this article
on BioMed Central
on Google Scholar
on PubMed Central
Other articles by authors
on Google Scholar

Stathopoulos EN
Dambaki C
Kampa M
Theodoropoulos PA
Anezinis P
Delakas D
Delides GS
Castanas E

on PubMed

Stathopoulos EN
Dambaki C
Kampa M
Theodoropoulos PA
Anezinis P
Delakas D
Delides GS
Castanas E
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research article

Membrane androgen binding sites are preferentially expressed in human prostate carcinoma cells

Efstathios N Stathopoulos¹ , Constantina Dambaki¹ , Marilena Kampa² , Panayiotis A Theodoropoulos³ , Ploutarchos Anezinis⁴ , Dimitrios Delakas⁴ , George S Delides¹ and Elias Castanas²

¹Department of Pathology, University of Crete, School of Medicine, Heraklion, Greece

²Department of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion, Greece

³Department of Biochemistry, University of Crete, School of Medicine, Heraklion, Greece

⁴Urology, University of Crete, School of Medicine, Heraklion, Greece

author email corresponding author email

BMC Clinical Pathology 2003, 3:1doi:10.1186/1472-6890-3-1


Published:	30 January 2003

Abstract

Background

Prostate cancer is one of the most frequent malignancies in males. Nevertheless, to this moment, there is no specific routine diagnostic marker to be used in clinical practice. Recently, the identification of a membrane testosterone binding site involved in the remodeling of actin cytoskeleton structures and PSA secretion, on LNCaP human prostate cancer cells has been reported. We have investigated whether this membrane testosterone binding component could be of value for the identification of prostate cancer.

Methods

Using a non-internalizable testosterone-BSA-FITC analog, proven to bind on membrane sites only in LNCaP cells, we have investigated the expression of membrane testosterone binding sites in a series of prostate carcinomas (n = 14), morphologically normal epithelia, taken from areas of the surgical specimens far from the location of the carcinomas (n = 8) and benign prostate hyperplasia epithelia (n = 10). Isolated epithelial cells were studied by flow cytometry, and touching preparations, after 10-min incubation. In addition, routine histological slides were assayed by confocal laser microscopy.

Results

We show that membrane testosterone binding sites are preferentially expressed in prostate carcinoma cells, while BPH and non-malignant epithelial cells show a low or absent binding.

Conclusions

Our results indicate that membrane testosterone receptors might be of use for the rapid routine identification of prostate cancer, representing a new diagnostic marker of the disease.